Cyxone (publ) announced chief medical officer (CMO) Cornel Pater leaves the company with immediate effect due to personal reasons. The planned phase 2b study in rheumatoid arthritis (RA) is advancing and the intermediate situation will be covered by Cyxone's management team and medical advisors. Recruitment of a new CMO has started.